CROSSROADS STRATEGIES, LLC for BRISTOL-MYERS SQUIBB
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SALIM ALAMEDDIN | — |
| BRITTANY JOHNSON HERNANDEZ | — |
| CHERYL LYNN JAEGER | — |
| MATHEW LAPINSKI | — |
| HUNTER MOORHEAD | — |
| JASON BENJAMIN VAN PELT | — |
| STEPHEN THOMAS VOLJAVEC | — |
Taxation/Internal Revenue Code TAX
Issues related to tax reform; R&D tax credit; international taxation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SALIM ALAMEDDIN | — |
| BRITTANY JOHNSON HERNANDEZ | — |
| CHERYL LYNN JAEGER | — |
| MATHEW LAPINSKI | — |
| HUNTER MOORHEAD | — |
| JASON BENJAMIN VAN PELT | — |
| STEPHEN THOMAS VOLJAVEC | — |
Copyright/Patent/Trademark CPT
Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SALIM ALAMEDDIN | — |
| BRITTANY JOHNSON HERNANDEZ | — |
| CHERYL LYNN JAEGER | — |
| MATHEW LAPINSKI | — |
| HUNTER MOORHEAD | — |
| JASON BENJAMIN VAN PELT | — |
| STEPHEN THOMAS VOLJAVEC | — |
Trade (domestic/foreign) TRD
Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SALIM ALAMEDDIN | — |
| BRITTANY JOHNSON HERNANDEZ | — |
| CHERYL LYNN JAEGER | — |
| MATHEW LAPINSKI | — |
| HUNTER MOORHEAD | — |
| JASON BENJAMIN VAN PELT | — |
| STEPHEN THOMAS VOLJAVEC | — |
Health Issues HCR
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, and PBM reform; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SALIM ALAMEDDIN | — |
| BRITTANY JOHNSON HERNANDEZ | — |
| CHERYL LYNN JAEGER | — |
| MATHEW LAPINSKI | — |
| HUNTER MOORHEAD | — |
| JASON BENJAMIN VAN PELT | — |
| STEPHEN THOMAS VOLJAVEC | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.